Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 …
…, Y Shparyk, S Cardona-Huerta, KL Cheung… - The Lancet, 2016 - thelancet.com
Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally
advanced or metastatic breast cancer. We investigated whether the selective oestrogen …
advanced or metastatic breast cancer. We investigated whether the selective oestrogen …
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone …
Background The optimum endocrine treatment for postmenopausal women with advanced
hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase …
hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase …
Concepts of seroma formation and prevention in breast cancer surgery
…, AA Ayantunde, KL Cheung - ANZ Journal of surgery, 2006 - Wiley Online Library
Background: Seroma formation is the commonest early sequel to breast cancer surgery
especially when axillary dissection is undertaken. It is associated with significant morbidity and …
especially when axillary dissection is undertaken. It is associated with significant morbidity and …
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists …
…, IH Kunkler, MJ Cardoso, KL Cheung… - The Lancet …, 2021 - thelancet.com
Breast cancer is increasingly prevalent in older adults and is a substantial part of routine
oncology practice. However, management of breast cancer in this population is challenging …
oncology practice. However, management of breast cancer in this population is challenging …
Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition
Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive
phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and …
phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and …
Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative
In 2011, the International Society of Geriatric Oncology (SIOG) published the SIOG 10 Priorities
Initiative, which defined top priorities for the improvement of the care of older adults with …
Initiative, which defined top priorities for the improvement of the care of older adults with …
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 …
The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer
in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of …
in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of …
Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women-an Asian population …
KP Hsieh, LC Chen, KL Cheung, CS Chang… - PLoS One, 2014 - journals.plos.org
This study aimed to evaluate the survival rate of women with breast cancer (BC) comparing
persistence versus interruption and adherence versus non-adherence to adjuvant hormonal …
persistence versus interruption and adherence versus non-adherence to adjuvant hormonal …
Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy
Invasive lobular carcinoma comprises 10–15% of all breast cancers and is increasingly
recognised as a distinct and understudied disease compared with the predominant histological …
recognised as a distinct and understudied disease compared with the predominant histological …
Cytoplasmic cyclin E predicts recurrence in patients with breast cancer
Purpose: Low molecular weight cyclin E (LMW-E) detected by Western blot analysis predicts
for reduced breast cancer survival; however, it is impractical for clinical use. LMW-E lacks a …
for reduced breast cancer survival; however, it is impractical for clinical use. LMW-E lacks a …
